Copyright Reports & Markets. All rights reserved.

Global Solid Tumors Drugs Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Players Covered: Ranking by Solid Tumors Drugs Revenue
  • 1.4 Market by Type
    • 1.4.1 Global Solid Tumors Drugs Market Size Growth Rate by Type: 2020 VS 2026
    • 1.4.2 Small Molecules
    • 1.4.3 Biologics
  • 1.5 Market by Application
    • 1.5.1 Global Solid Tumors Drugs Market Share by Application: 2020 VS 2026
    • 1.5.2 Hospitals
    • 1.5.3 Clinics
    • 1.5.4 Academic and Research Institutes
  • 1.6 Study Objectives
  • 1.7 Years Considered

2 Global Growth Trends

  • 2.1 Global Solid Tumors Drugs Market Perspective (2015-2026)
  • 2.2 Global Solid Tumors Drugs Growth Trends by Regions
    • 2.2.1 Solid Tumors Drugs Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Solid Tumors Drugs Historic Market Share by Regions (2015-2020)
    • 2.2.3 Solid Tumors Drugs Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Top Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Porter’s Five Forces Analysis
    • 2.3.5 Solid Tumors Drugs Market Growth Strategy
    • 2.3.6 Primary Interviews with Key Solid Tumors Drugs Players (Opinion Leaders)

3 Competition Landscape by Key Players

  • 3.1 Global Top Solid Tumors Drugs Players by Market Size
    • 3.1.1 Global Top Solid Tumors Drugs Players by Revenue (2015-2020)
    • 3.1.2 Global Solid Tumors Drugs Revenue Market Share by Players (2015-2020)
    • 3.1.3 Global Solid Tumors Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.2 Global Solid Tumors Drugs Market Concentration Ratio
    • 3.2.1 Global Solid Tumors Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.2.2 Global Top 10 and Top 5 Companies by Solid Tumors Drugs Revenue in 2019
  • 3.3 Solid Tumors Drugs Key Players Head office and Area Served
  • 3.4 Key Players Solid Tumors Drugs Product Solution and Service
  • 3.5 Date of Enter into Solid Tumors Drugs Market
  • 3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

  • 4.1 Global Solid Tumors Drugs Historic Market Size by Type (2015-2020)
  • 4.2 Global Solid Tumors Drugs Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)

  • 5.1 Global Solid Tumors Drugs Market Size by Application (2015-2020)
  • 5.2 Global Solid Tumors Drugs Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Solid Tumors Drugs Market Size (2015-2020)
  • 6.2 Solid Tumors Drugs Key Players in North America (2019-2020)
  • 6.3 North America Solid Tumors Drugs Market Size by Type (2015-2020)
  • 6.4 North America Solid Tumors Drugs Market Size by Application (2015-2020)

7 Europe

  • 7.1 Europe Solid Tumors Drugs Market Size (2015-2020)
  • 7.2 Solid Tumors Drugs Key Players in Europe (2019-2020)
  • 7.3 Europe Solid Tumors Drugs Market Size by Type (2015-2020)
  • 7.4 Europe Solid Tumors Drugs Market Size by Application (2015-2020)

8 China

  • 8.1 China Solid Tumors Drugs Market Size (2015-2020)
  • 8.2 Solid Tumors Drugs Key Players in China (2019-2020)
  • 8.3 China Solid Tumors Drugs Market Size by Type (2015-2020)
  • 8.4 China Solid Tumors Drugs Market Size by Application (2015-2020)

9 Japan

  • 9.1 Japan Solid Tumors Drugs Market Size (2015-2020)
  • 9.2 Solid Tumors Drugs Key Players in Japan (2019-2020)
  • 9.3 Japan Solid Tumors Drugs Market Size by Type (2015-2020)
  • 9.4 Japan Solid Tumors Drugs Market Size by Application (2015-2020)

10 Southeast Asia

  • 10.1 Southeast Asia Solid Tumors Drugs Market Size (2015-2020)
  • 10.2 Solid Tumors Drugs Key Players in Southeast Asia (2019-2020)
  • 10.3 Southeast Asia Solid Tumors Drugs Market Size by Type (2015-2020)
  • 10.4 Southeast Asia Solid Tumors Drugs Market Size by Application (2015-2020)

11 India

  • 11.1 India Solid Tumors Drugs Market Size (2015-2020)
  • 11.2 Solid Tumors Drugs Key Players in India (2019-2020)
  • 11.3 India Solid Tumors Drugs Market Size by Type (2015-2020)
  • 11.4 India Solid Tumors Drugs Market Size by Application (2015-2020)

12 Central & South America

  • 12.1 Central & South America Solid Tumors Drugs Market Size (2015-2020)
  • 12.2 Solid Tumors Drugs Key Players in Central & South America (2019-2020)
  • 12.3 Central & South America Solid Tumors Drugs Market Size by Type (2015-2020)
  • 12.4 Central & South America Solid Tumors Drugs Market Size by Application (2015-2020)

13 Key Players Profiles

  • 13.1 Hoffmann-La Roche
    • 13.1.1 Hoffmann-La Roche Company Details
    • 13.1.2 Hoffmann-La Roche Business Overview
    • 13.1.3 Hoffmann-La Roche Solid Tumors Drugs Introduction
    • 13.1.4 Hoffmann-La Roche Revenue in Solid Tumors Drugs Business (2015-2020))
    • 13.1.5 Hoffmann-La Roche Recent Development
  • 13.2 Novartis
    • 13.2.1 Novartis Company Details
    • 13.2.2 Novartis Business Overview
    • 13.2.3 Novartis Solid Tumors Drugs Introduction
    • 13.2.4 Novartis Revenue in Solid Tumors Drugs Business (2015-2020)
    • 13.2.5 Novartis Recent Development
  • 13.3 Celgene
    • 13.3.1 Celgene Company Details
    • 13.3.2 Celgene Business Overview
    • 13.3.3 Celgene Solid Tumors Drugs Introduction
    • 13.3.4 Celgene Revenue in Solid Tumors Drugs Business (2015-2020)
    • 13.3.5 Celgene Recent Development
  • 13.4 Johnson & Johnson
    • 13.4.1 Johnson & Johnson Company Details
    • 13.4.2 Johnson & Johnson Business Overview
    • 13.4.3 Johnson & Johnson Solid Tumors Drugs Introduction
    • 13.4.4 Johnson & Johnson Revenue in Solid Tumors Drugs Business (2015-2020)
    • 13.4.5 Johnson & Johnson Recent Development
  • 13.5 Pfizer
    • 13.5.1 Pfizer Company Details
    • 13.5.2 Pfizer Business Overview
    • 13.5.3 Pfizer Solid Tumors Drugs Introduction
    • 13.5.4 Pfizer Revenue in Solid Tumors Drugs Business (2015-2020)
    • 13.5.5 Pfizer Recent Development
  • 13.6 BMS
    • 13.6.1 BMS Company Details
    • 13.6.2 BMS Business Overview
    • 13.6.3 BMS Solid Tumors Drugs Introduction
    • 13.6.4 BMS Revenue in Solid Tumors Drugs Business (2015-2020)
    • 13.6.5 BMS Recent Development
  • 13.7 Eli Lilly
    • 13.7.1 Eli Lilly Company Details
    • 13.7.2 Eli Lilly Business Overview
    • 13.7.3 Eli Lilly Solid Tumors Drugs Introduction
    • 13.7.4 Eli Lilly Revenue in Solid Tumors Drugs Business (2015-2020)
    • 13.7.5 Eli Lilly Recent Development
  • 13.8 GSK
    • 13.8.1 GSK Company Details
    • 13.8.2 GSK Business Overview
    • 13.8.3 GSK Solid Tumors Drugs Introduction
    • 13.8.4 GSK Revenue in Solid Tumors Drugs Business (2015-2020)
    • 13.8.5 GSK Recent Development
  • 13.9 Merck
    • 13.9.1 Merck Company Details
    • 13.9.2 Merck Business Overview
    • 13.9.3 Merck Solid Tumors Drugs Introduction
    • 13.9.4 Merck Revenue in Solid Tumors Drugs Business (2015-2020)
    • 13.9.5 Merck Recent Development
  • 13.10 Sanofi
    • 13.10.1 Sanofi Company Details
    • 13.10.2 Sanofi Business Overview
    • 13.10.3 Sanofi Solid Tumors Drugs Introduction
    • 13.10.4 Sanofi Revenue in Solid Tumors Drugs Business (2015-2020)
    • 13.10.5 Sanofi Recent Development
  • 13.11 AbbVie
    • 10.11.1 AbbVie Company Details
    • 10.11.2 AbbVie Business Overview
    • 10.11.3 AbbVie Solid Tumors Drugs Introduction
    • 10.11.4 AbbVie Revenue in Solid Tumors Drugs Business (2015-2020)
    • 10.11.5 AbbVie Recent Development
  • 13.12 AstraZeneca
    • 10.12.1 AstraZeneca Company Details
    • 10.12.2 AstraZeneca Business Overview
    • 10.12.3 AstraZeneca Solid Tumors Drugs Introduction
    • 10.12.4 AstraZeneca Revenue in Solid Tumors Drugs Business (2015-2020)
    • 10.12.5 AstraZeneca Recent Development
  • 13.13 Bayer
    • 10.13.1 Bayer Company Details
    • 10.13.2 Bayer Business Overview
    • 10.13.3 Bayer Solid Tumors Drugs Introduction
    • 10.13.4 Bayer Revenue in Solid Tumors Drugs Business (2015-2020)
    • 10.13.5 Bayer Recent Development
  • 13.14 Biogen
    • 10.14.1 Biogen Company Details
    • 10.14.2 Biogen Business Overview
    • 10.14.3 Biogen Solid Tumors Drugs Introduction
    • 10.14.4 Biogen Revenue in Solid Tumors Drugs Business (2015-2020)
    • 10.14.5 Biogen Recent Development
  • 13.15 Boehringer Ingelheim
    • 10.15.1 Boehringer Ingelheim Company Details
    • 10.15.2 Boehringer Ingelheim Business Overview
    • 10.15.3 Boehringer Ingelheim Solid Tumors Drugs Introduction
    • 10.15.4 Boehringer Ingelheim Revenue in Solid Tumors Drugs Business (2015-2020)
    • 10.15.5 Boehringer Ingelheim Recent Development
  • 13.16 Boston Biomedical
    • 10.16.1 Boston Biomedical Company Details
    • 10.16.2 Boston Biomedical Business Overview
    • 10.16.3 Boston Biomedical Solid Tumors Drugs Introduction
    • 10.16.4 Boston Biomedical Revenue in Solid Tumors Drugs Business (2015-2020)
    • 10.16.5 Boston Biomedical Recent Development
  • 13.17 Daiichi Sankyo
    • 10.17.1 Daiichi Sankyo Company Details
    • 10.17.2 Daiichi Sankyo Business Overview
    • 10.17.3 Daiichi Sankyo Solid Tumors Drugs Introduction
    • 10.17.4 Daiichi Sankyo Revenue in Solid Tumors Drugs Business (2015-2020)
    • 10.17.5 Daiichi Sankyo Recent Development

14 Analyst's Viewpoints/Conclusions

    15 Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Disclaimer

    Solid Tumors Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Solid Tumors Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    The key players covered in this study
    Hoffmann-La Roche
    Novartis
    Celgene
    Johnson & Johnson
    Pfizer
    BMS
    Eli Lilly
    GSK
    Merck
    Sanofi
    AbbVie
    AstraZeneca
    Bayer
    Biogen
    Boehringer Ingelheim
    Boston Biomedical
    Daiichi Sankyo

    Market segment by Type, the product can be split into
    Small Molecules
    Biologics
    Market segment by Application, split into
    Hospitals
    Clinics
    Academic and Research Institutes

    Market segment by Regions/Countries, this report covers
    North America
    Europe
    China
    Japan
    Southeast Asia
    India
    Central & South America

    Buy now